Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
May 16, 2024 08:30 ET
|
Avenue Therapeutics
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 16, 2024 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15, 2024 16:15 ET
|
Fortress Biotech, Inc.
Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA...
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 15, 2024 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15, 2024 08:30 ET
|
Avenue Therapeutics
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue”...
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
May 14, 2024 08:30 ET
|
Fortress Biotech, Inc.
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 13, 2024 16:01 ET
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%...
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 10, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
May 07, 2024 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...